2018 Annual Meeting | C151 - Cerebrovascular Disease III: Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke

Date Wednesday 04/25/18

Time 01:00 PM - 03:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Philip B. Gorelick, MD, MPH, FAAN

Topic(s)

Learning Objectives Participants should be able to identify indications for intravenous alteplase in acute ischemic stroke treatment, apply neuroimaging modalities to select patients for acute ischemic stroke treatment, and be familiar with indications for endovascular interventions.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Tracks Neurohospitalist

Recommended Audience Other, Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist

Teaching Styles Case-based, Didactic

Event Timeline
01:00 PM - 01:15 PM	Speaker	Indications for Intravenous Alteplase Philip B. Gorelick, MD, MPH, FAAN
01:15 PM - 01:55 PM	Speaker	Neuroimaging - the Precision Medicine of Acute Ischemic Stroke David S. Liebeskind, MD, FAAN
01:55 PM - 02:05 PM	Q&A	Questions and Answers
02:05 PM - 02:45 PM	Speaker	Update on Endovascular Intervention for Acute Ischemic Stroke Ashutosh P. Jadhav, MD, FAAN
02:45 PM - 02:55 PM	Q&A	Questions and Answers
02:55 PM - 03:00 PM	Closing Remarks	Closing Remarks Philip B. Gorelick, MD, MPH, FAAN

Faculty Disclosures
Philip B. Gorelick, MD, MPH, FAAN	Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AMGEN. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. Dr. Gorelick has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Thorek Memorial Hospital. Dr. Gorelick has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Thorek Memorial Hospital.
David S. Liebeskind, MD, FAAN	Dr. Liebeskind has received research support from Cerenovus. Dr. Liebeskind has received research support from Genentech . Dr. Liebeskind has received research support from Medtronic. Dr. Liebeskind has received research support from Stryker.
Tudor G. Jovin, MD	Dr. Jovin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerenovus. Dr. Jovin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Contego Medical. Dr. Jovin has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Several law firms. Dr. Jovin has stock in Corindus. Dr. Jovin has stock in Methinks. Dr. Jovin has stock in Viz.ai. Dr. Jovin has stock in Route92. Dr. Jovin has stock in FreeOx Biotech. Dr. Jovin has stock in Galaxy. Dr. Jovin has stock in Kandu. The institution of Dr. Jovin has received research support from Stryker. The institution of Dr. Jovin has received research support from Medtronic.
Ashutosh P. Jadhav, MD, FAAN	Dr. Jadhav has nothing to disclose.

��ɫ��

��ɫ��